Skip to main content

CORRECTION article

Front. Pharmacol., 12 January 2023
Sec. Pharmacology of Anti-Cancer Drugs
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1125890

Corrigendum: R-carvedilol, a potential new therapy for Alzheimer’s disease

This article is a correction to:

  1. R-carvedilol, a potential new therapy for Alzheimer’s disease

    1. Read original article
Jinjing Yao, Jinjing Yao1,2*S. R. Wayne Chen, S. R. Wayne Chen1,2*
  • 1Department of Physiology and Pharmacology, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada
  • 2Department of Physiology and Pharmacology, Cumming School of Medicine, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada

A Corrigendum on
R-carvedilol, a potential new therapy for Alzheimer’s disease

by Yao J and Chen SRW (2022). Front. Pharmacol. 13:1062495. doi: 10.3389/fphar.2022.1062495

In the published article, there was an error in the Acknowledgements statement as Krembil Foundation was accidentally omitted. The corrected statement appears below.

Acknowledgments

“This work was supported by research grants from the Canadian Institutes of Health Research (PJT-152914) and the Heart and Stroke Foundation Chair in Cardiovascular Research (END611955) to SC. We also gratefully acknowledge the generous support from the Krembil Foundation.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: carvedilol, R-carvedilol, Alzheimer’s disease, RyR2, neuronal hyperactivity

Citation: Yao J and Chen SRW (2023) Corrigendum: R-carvedilol, a potential new therapy for Alzheimer’s disease. Front. Pharmacol. 13:1125890. doi: 10.3389/fphar.2022.1125890

Received: 20 December 2022; Accepted: 20 December 2022;
Published: 12 January 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Yao and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jinjing Yao, amluamluZy55YW9AdWNhbGdhcnkuY2E=; S. R. Wayne Chen, c3djaGVuQHVjYWxnYXJ5LmNh

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.